BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD4512 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD4512\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07123454-11147@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20280704
DTEND;VALUE=DATE:20280705
SUMMARY:AZD4512: Phase 1/2 readout est. (NCT07123454)
DESCRIPTION:AZD4512\, phase 1/2\, B-Cell Non-Hodgkin Lymphoma.\nStudy: A Ph
 ase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Ag
 ents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma\
 nEstimated primary completion: 4 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/azd4512#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07123454
URL:https://assetmemo.bio/drug/azd4512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109219-11147@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20281011
DTEND;VALUE=DATE:20281012
SUMMARY:AZD4512: Phase 1/2 readout est. (NCT07109219)
DESCRIPTION:AZD4512\, phase 1/2.\nStudy: Study of AZD4512 Monotherapy or in
  Combination With Anticancer Agents in Participants With Acute Lymphoblast
 ic Leukemia\nEstimated primary completion: 11 October 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azd4512#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07109219
URL:https://assetmemo.bio/drug/azd4512#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
